{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lévorphanol : Questions médicales les plus fréquentes",
"headline": "Lévorphanol : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lévorphanol : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-13",
"dateModified": "2025-03-10",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lévorphanol"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Morphinanes",
"url": "https://questionsmedicales.fr/mesh/D009019",
"about": {
"@type": "MedicalCondition",
"name": "Morphinanes",
"code": {
"@type": "MedicalCode",
"code": "D009019",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.723.795"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Lévorphanol",
"alternateName": "Levorphanol",
"code": {
"@type": "MedicalCode",
"code": "D007981",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ali Haider",
"url": "https://questionsmedicales.fr/author/Ali%20Haider",
"affiliation": {
"@type": "Organization",
"name": "Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA."
}
},
{
"@type": "Person",
"name": "Akhila Reddy",
"url": "https://questionsmedicales.fr/author/Akhila%20Reddy",
"affiliation": {
"@type": "Organization",
"name": "Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. asreddy@mdanderson.org."
}
},
{
"@type": "Person",
"name": "Valerie Le Rouzic",
"url": "https://questionsmedicales.fr/author/Valerie%20Le%20Rouzic",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Neurology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York."
}
},
{
"@type": "Person",
"name": "Ankita Narayan",
"url": "https://questionsmedicales.fr/author/Ankita%20Narayan",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Neurology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York."
}
},
{
"@type": "Person",
"name": "Amanda Hunkle",
"url": "https://questionsmedicales.fr/author/Amanda%20Hunkle",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Neurology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cross-sectional quantitative validation of the paediatric Localized Scleroderma Quality of Life Instrument (LoSQI): A disease-specific patient-reported outcome measure.",
"datePublished": "2023-04-12",
"url": "https://questionsmedicales.fr/article/36950970",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jdv.19059"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Reactivation of Scleroderma After Autologous Fat Grafting.",
"datePublished": "2023-08-15",
"url": "https://questionsmedicales.fr/article/37582285",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/SCS.0000000000009614"
}
},
{
"@type": "ScholarlyArticle",
"name": "Scleroderma autoantibodies in guiding monitoring and treatment decisions.",
"datePublished": "2022-08-29",
"url": "https://questionsmedicales.fr/article/36082759",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/BOR.0000000000000904"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mental health symptoms in scleroderma during COVID-19: a Scleroderma Patient-centred Intervention Network (SPIN) cohort longitudinal study.",
"datePublished": "2023-04-19",
"url": "https://questionsmedicales.fr/article/37083160",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.55563/clinexprheumatol/cca0xv"
}
},
{
"@type": "ScholarlyArticle",
"name": "Juvenile and adult-onset scleroderma: Different clinical phenotypes.",
"datePublished": "2023-03-29",
"url": "https://questionsmedicales.fr/article/37031645",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.semarthrit.2023.152197"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011083"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures aromatiques polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011084"
},
{
"@type": "ListItem",
"position": 4,
"name": "Phénanthrènes",
"item": "https://questionsmedicales.fr/mesh/D010616"
},
{
"@type": "ListItem",
"position": 5,
"name": "Morphinanes",
"item": "https://questionsmedicales.fr/mesh/D009019"
},
{
"@type": "ListItem",
"position": 6,
"name": "Lévorphanol",
"item": "https://questionsmedicales.fr/mesh/D007981"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lévorphanol - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lévorphanol",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lévorphanol",
"description": "Comment diagnostiquer une douleur nécessitant du lévorphanol ?\nQuels tests sont utilisés pour évaluer la douleur ?\nLe lévorphanol est-il prescrit pour tous les types de douleur ?\nQuels critères déterminent l'utilisation du lévorphanol ?\nLe lévorphanol est-il utilisé en cas de douleur chronique ?",
"url": "https://questionsmedicales.fr/mesh/D007981?mesh_terms=Scleroderma,+Localized&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lévorphanol",
"description": "Quels sont les effets secondaires du lévorphanol ?\nLe lévorphanol peut-il provoquer des réactions allergiques ?\nQuels symptômes indiquent une surdose de lévorphanol ?\nComment reconnaître une dépendance au lévorphanol ?\nLe lévorphanol peut-il affecter l'humeur ?",
"url": "https://questionsmedicales.fr/mesh/D007981?mesh_terms=Scleroderma,+Localized&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lévorphanol",
"description": "Comment prévenir les effets secondaires du lévorphanol ?\nQuelles précautions prendre avant de commencer le lévorphanol ?\nLe lévorphanol est-il sûr pour les personnes âgées ?\nComment éviter la dépendance au lévorphanol ?\nQuelles alternatives au lévorphanol existent ?",
"url": "https://questionsmedicales.fr/mesh/D007981?mesh_terms=Scleroderma,+Localized&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lévorphanol",
"description": "Comment le lévorphanol est-il administré ?\nQuelle est la posologie habituelle du lévorphanol ?\nLe lévorphanol peut-il être combiné avec d'autres analgésiques ?\nQuels sont les risques d'un traitement prolongé au lévorphanol ?\nComment arrêter le lévorphanol en toute sécurité ?",
"url": "https://questionsmedicales.fr/mesh/D007981?mesh_terms=Scleroderma,+Localized&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lévorphanol",
"description": "Quelles complications peuvent survenir avec le lévorphanol ?\nLe lévorphanol peut-il interagir avec d'autres médicaments ?\nComment gérer une réaction allergique au lévorphanol ?\nQuels sont les signes d'une surdose de lévorphanol ?\nLe lévorphanol peut-il causer des problèmes cardiaques ?",
"url": "https://questionsmedicales.fr/mesh/D007981?mesh_terms=Scleroderma,+Localized&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lévorphanol",
"description": "Qui est à risque de dépendance au lévorphanol ?\nLes jeunes adultes sont-ils plus à risque avec le lévorphanol ?\nQuels facteurs augmentent le risque d'effets secondaires ?\nLe lévorphanol est-il risqué pour les femmes enceintes ?\nLes personnes ayant des problèmes respiratoires sont-elles à risque ?",
"url": "https://questionsmedicales.fr/mesh/D007981?mesh_terms=Scleroderma,+Localized&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une douleur nécessitant du lévorphanol ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic se fait par évaluation clinique et historique médical du patient."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la douleur ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des échelles de douleur et des examens physiques sont utilisés pour évaluer l'intensité."
}
},
{
"@type": "Question",
"name": "Le lévorphanol est-il prescrit pour tous les types de douleur ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il est principalement utilisé pour la douleur modérée à sévère, pas pour la douleur légère."
}
},
{
"@type": "Question",
"name": "Quels critères déterminent l'utilisation du lévorphanol ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent l'intensité de la douleur et la réponse aux traitements antérieurs."
}
},
{
"@type": "Question",
"name": "Le lévorphanol est-il utilisé en cas de douleur chronique ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être utilisé pour la douleur chronique lorsque d'autres traitements échouent."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires du lévorphanol ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent la somnolence, la constipation et des nausées."
}
},
{
"@type": "Question",
"name": "Le lévorphanol peut-il provoquer des réactions allergiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réactions allergiques peuvent survenir, bien que rares."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une surdose de lévorphanol ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent la dépression respiratoire, la somnolence excessive et la confusion."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une dépendance au lévorphanol ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de dépendance incluent le besoin compulsif de médicament et des symptômes de sevrage."
}
},
{
"@type": "Question",
"name": "Le lévorphanol peut-il affecter l'humeur ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut provoquer des changements d'humeur, y compris l'euphorie ou la dépression."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets secondaires du lévorphanol ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance régulière et l'ajustement de la posologie peuvent aider à prévenir les effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre avant de commencer le lévorphanol ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informez votre médecin de vos antécédents médicaux et des médicaments que vous prenez."
}
},
{
"@type": "Question",
"name": "Le lévorphanol est-il sûr pour les personnes âgées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il doit être utilisé avec prudence chez les personnes âgées en raison du risque accru d'effets secondaires."
}
},
{
"@type": "Question",
"name": "Comment éviter la dépendance au lévorphanol ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utilisez-le uniquement selon les prescriptions et évitez l'auto-médication."
}
},
{
"@type": "Question",
"name": "Quelles alternatives au lévorphanol existent ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des alternatives incluent d'autres analgésiques opioïdes ou des traitements non opioïdes."
}
},
{
"@type": "Question",
"name": "Comment le lévorphanol est-il administré ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est généralement administré par voie orale ou intraveineuse selon la situation clinique."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie habituelle du lévorphanol ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie varie, mais commence souvent à 2-4 mg toutes les 6-8 heures selon la douleur."
}
},
{
"@type": "Question",
"name": "Le lévorphanol peut-il être combiné avec d'autres analgésiques ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être utilisé en association avec d'autres analgésiques pour un meilleur contrôle de la douleur."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'un traitement prolongé au lévorphanol ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement prolongé peut entraîner une tolérance, une dépendance et des effets secondaires accrus."
}
},
{
"@type": "Question",
"name": "Comment arrêter le lévorphanol en toute sécurité ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'arrêt doit être progressif sous supervision médicale pour éviter les symptômes de sevrage."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le lévorphanol ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la dépression respiratoire, la constipation sévère et la dépendance."
}
},
{
"@type": "Question",
"name": "Le lévorphanol peut-il interagir avec d'autres médicaments ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut interagir avec d'autres médicaments, augmentant le risque d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Comment gérer une réaction allergique au lévorphanol ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "En cas de réaction allergique, arrêtez le médicament et consultez immédiatement un médecin."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une surdose de lévorphanol ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent la somnolence extrême, la confusion et la difficulté à respirer."
}
},
{
"@type": "Question",
"name": "Le lévorphanol peut-il causer des problèmes cardiaques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut provoquer des problèmes cardiaques chez certains patients, surtout en cas de surdose."
}
},
{
"@type": "Question",
"name": "Qui est à risque de dépendance au lévorphanol ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant des antécédents de dépendance ou de troubles de l'humeur sont à risque."
}
},
{
"@type": "Question",
"name": "Les jeunes adultes sont-ils plus à risque avec le lévorphanol ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes adultes peuvent être plus susceptibles de développer une dépendance aux opioïdes."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets secondaires ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, les maladies chroniques et l'utilisation concomitante d'autres médicaments augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le lévorphanol est-il risqué pour les femmes enceintes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut présenter des risques pour le fœtus et doit être évité sauf en cas de nécessité."
}
},
{
"@type": "Question",
"name": "Les personnes ayant des problèmes respiratoires sont-elles à risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont à risque accru de dépression respiratoire lors de l'utilisation de lévorphanol."
}
}
]
}
]
}
The Localized Scleroderma Quality of Life Instrument (LoSQI) is a disease-specific patient-reported outcome (PRO) measure designed for children and adolescents with localized scleroderma (LS; morphea)...
The purpose of this study was to evaluate the psychometric properties of the LoSQI in a clinical setting....
Cross-sectional data from four specialized clinics in the US and Canada were included in the analysis. Evaluation included reliability of scores, internal structure of the survey, evidence of converge...
One hundred and ten patients with LS (age: 8-20 years) completed the LoSQI. Both exploratory and confirmatory factor analysis supported the use of two sub-scores: Pain and Physical Functioning, and Bo...
This study did not evaluate longitudinal validity or responsiveness of scores....
Results from a representative sample of children and adolescents with LS continue to support the validity of the LoSQI when used in a clinical setting. Future work to evaluate the responsiveness is on...
Patients with localized scleroderma (LS) often have to seek plastic surgery to improve facial esthetic impairment....
The authors reported a case of the reactivation of LS after autologous fat grafting (AFG)....
A man presented with facial atrophy and skin fibrosis on the cheek with a history of LS. The disease had remained stable for 9 years and he was suggested to stop oral medication. With irreversible est...
Six months after the last AFG, the patient found new lesions occur on the lateral forehead. The patient was later diagnosed with reactivation of LS....
The understanding of the surgical risk and perioperative management for patients with LS needs more research....
One of the key clinical challenges of systemic sclerosis (SSc) is diversity in clinical presentation, organ involvement and disease progression. Antinuclear autoantibodies (ANA) are central to the dia...
There has been further development in delineating clinical patterns in ANA, genetic susceptibility and antigen triggers predisposing to ANA subtypes. Sub-group analysis of recent clinical trials shows...
ANA subtyping is likely to be firmly embedded into future classification systems. Beyond informing current management and monitoring of scleroderma patients, ANA subsets have implication on future res...
People with systemic sclerosis (SSc) are vulnerable in COVID-19 and face challenges related to shifting COVID-19 risk and protective restrictions. We evaluated mental health symptom trajectories in pe...
The longitudinal Scleroderma Patient-centred Intervention Network (SPIN) COVID-19 cohort was launched in April 2020 and included participants from the ongoing SPIN Cohort and external enrolees. Analys...
Anxiety symptoms increased in early 2020 but returned to pre-COVID-19 levels by mid-2020 and remained stable through March 2022. Depression symptoms did not initially change but were slightly lower by...
People with SSc continue to face COVID-19 challenges related to ongoing risk, the opening of societies, and removal of protective restrictions. People with SSc, in aggregate, appear to be weathering t...
Systemic sclerosis (SSc) represents extremely rare disease with majority of data coming from adults. Studies comparing juvenile- (jSSc) and adult-onset (aSSc) patients are limited. We aimed to compare...
A retrospective study among pediatric and adult Scl patients has been performed. Demographic characteristics, clinical features, autoantibody profiles, and treatment data were retrieved from the datab...
A total of 158 adults and 58 juvenile Scl patients were identified. The mean age at the disease onset was 37±14.7 vs. 8.8 ± 4.1 years, mean age at diagnosis 42±15.2 vs. 10.4 ± 3.8 years and mean follo...
Juvenile and adult-onset Scl represent rarely seen conditions with different clinical phenotypes. Pediatric patients with LS are more commonly seen by pediatric rheumatologists, in contrary to adults....
We investigated the ability of a panel of immune-related cytokines and chemokines to predict the disease activity state in localized scleroderma (LS) subjects followed longitudinally. A total of 194 s...
Systemic sclerosis (SSc) is characterized by the presence of SSc-specific or SSc-associated antibodies (SSc-Abs): anti-topoisomerase I (ATA), anti-centromere (ACA), anti-RNA polymerase III (ARA), anti...
Erectile dysfunction (ED) has been reported among patients with systemic sclerosis (SSc) and primarily limited cutaneous SSc in Caucasians. While there is no data on ED among Thais in whom the diffuse...
We aimed to estimate the prevalence of ED among Thais with SSc, evaluate its severity, and determine the associated factors....
We did a cross-sectional study among adult Thai male SSc patients. All eligible patients: a) completed the IIEF-15 questionnaire by themselves; b) underwent a genital examination by an experienced uro...
A total of 60 male SSc patients were included. The respective mean age and median disease duration was 54.8±7.2 years and 3.1 years (IQR 1.2-7.2). The definition of ED was fulfilled in 53 cases for a ...
ED is a common problem in men with SSc and is mainly categorized as severe. The severity of SSc might increase the risk of developing ED. We found phimosis was a common genital abnormality co-occurrin...
Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc) with a mortality of 20% at 6 months. Once the leading cause of mortality in scleroderma (SSc), it remains ...
Morphea presenting clinically with nodular or keloidal skin changes is extremely rare. Nodular scleroderma or keloidal morphea presenting in a linear distribution is even more uncommon. We present an ...